Meoly Wart Corn Remover

Description

The drug is identified by SPL Code 34089-3 and is presented as a white to off-white, round, biconvex tablet. The tablet is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. Inactive ingredients consist of lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the removal of common warts, plantar warts, flat warts, corns, and calluses.

There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

Healthcare professionals should instruct patients to dip the brush into the liquid and apply it directly to the affected area. Following application, it is essential to allow the solution to turn into a mask.

Patients are advised to continue this daily application for a minimum of 2 weeks, or until the skin appears smooth. In cases of more severe conditions, an extended duration of treatment may be necessary to achieve the desired results.

Contraindications

Use of this product is contraindicated in the following situations:

Application on the facial or eye area is prohibited due to the potential for irritation and adverse reactions. Additionally, the product should not be applied to damaged or cut skin, including wounds, grazes, eczema, or sunburn, as this may exacerbate the condition or lead to further complications. Furthermore, individuals with a known allergy to this product should avoid its use to prevent allergic reactions.

Warnings and Precautions

For external use only; this product should be kept out of reach of children to prevent accidental ingestion or misuse.

In the event of accidental swallowing, it is imperative to seek emergency medical assistance immediately or contact the Poison Control Center for guidance.

Healthcare professionals should advise patients to discontinue use and consult a physician if any signs of irritation or rash develop during treatment. Monitoring for these adverse reactions is essential to ensure patient safety and effective management of any potential side effects.

Side Effects

Patients should be aware that the product is intended for external use only and must be kept out of reach of children to prevent accidental ingestion or misuse.

In clinical practice, it is advised that patients discontinue use and consult a healthcare professional if any irritation or rash develops during treatment. This precaution is essential to ensure the safety and well-being of the patient.

Overall, while the product is generally well-tolerated, monitoring for adverse reactions is recommended to address any potential issues promptly.

Drug Interactions

There are no reported drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Meoly Wart Corn Remover (wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

There is no information available regarding the use of this drug during pregnancy, including safety concerns, dosage modifications, or any special precautions that should be taken. Healthcare professionals are advised to consider the lack of data when prescribing this medication to pregnant patients and to weigh the potential risks and benefits. Women of childbearing potential should be counseled accordingly.

Lactation

Nursing mothers should exercise caution when using this product due to the potential for excretion in breast milk. It is recommended that lactating mothers consult a healthcare provider before using this product while breastfeeding to assess any potential risks to the infant.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Furthermore, it is crucial to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable. Continuous assessment and supportive measures should be prioritized until the patient stabilizes or further treatment is determined.

Documentation of the incident, including the substance involved, estimated dose, time of ingestion, and any symptoms observed, is vital for ongoing management and potential reporting requirements.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact the Poison Control Center immediately.

Patients should be informed not to use the product on the facial or eye area, or on damaged or cut skin, including wounds, grazes, eczema, or sunburn. It is important to discuss any known allergies to the product, as this may contraindicate its use.

Healthcare providers should counsel patients to discontinue use and consult a doctor if they experience any irritation or rash. Additionally, patients should be reminded to avoid contact with the eyes, ears, mouth, and any open or injured skin areas while using the product. In the event of contact with the eyes, patients should rinse their eyes thoroughly with water.

Storage and Handling

The product is supplied in a sealed bottle. It is essential to store the bottle in a shady place to maintain its integrity and effectiveness. Proper storage conditions are crucial for ensuring the product remains stable and safe for use.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Meoly Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)